Table 1.
Data From mRNA Vaccine Skin Testing
| Demographics |
Previous medical history |
Pfizer-BioNTech COVID-19 vaccine |
Moderna COVID-19 vaccine |
COVID-19 vaccination history |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skin test reactiona |
Skin test reactiona |
|||||||||||||||
| Date tested | Pt | Age | Sex | Anaphylaxis |
Self-reported reactions to products containing PEG |
COVID-19 infection | Immediate | LPR | Delayed | Immediate | LPR | Delayed | COVID-19 vaccinationb | Anaphylaxis to vaccination | ||
| Self-reported history | Self-reported cause | Toothpaste | Colonoscopy prep | |||||||||||||
| January 22, 2021 | 1 | 54 | F | Yes | Food, lidocaine | No | Yes | Yesc | Neg | Pos | No data | Not tested | Not tested | Not tested | Janssen (4/30) | None |
| January 22, 2021 | 2 | 80 | F | Yes | Environmentals, animal | Yes | No | No | Neg | Pos | No data | Not tested | Not tested | Not tested | Janssen recommended | N/A |
| January 22, 2021 | 3 | 65 | F | Yes | Foods | No | No | No | Neg | Neg | No data | Not tested | Not tested | Not tested | Moderna (3/5) | None |
| January 22, 2021 | 4 | 77 | F | Yes | Meds, foods | Yes | No | No | Neg | Neg | No data | Not tested | Not tested | Not tested | Pfizer (2/1, 2/22) | None |
| January 22, 2021 | 5 | 59 | F | Yes | Food | No | No | No | Neg | Neg | No data | Not tested | Not tested | Not tested | Did not receive | N/A |
| January 22, 2021 | 6 | 74 | F | Yes | Foods, cosmetics | Yes | No | No | Neg | Neg | No data | Not tested | Not tested | Not tested | Pfizer (2/12, 3/5) | None |
| January 22, 2021 | 7 | 62 | F | Yes | Foods | Yes | No | No | Neg | Neg | No data | Not tested | Not tested | Not tested | Moderna (3/18, 4/25) | None |
| January 22, 2021 | 8 | 74 | F | Yes | Mold | Yes | No | No | Neg | Neg | No data | Not tested | Not tested | Not tested | Pfizer (3/2, 3/23) | None |
| January 22, 2021 | 9 | 77 | F | Yes | Food, contrast media | No | No | No | Neg | Neg | Pos | Not tested | Not tested | Not tested | Pfizer (2/8, 3/1) | None |
| January 22, 2021 | 10 | 27 | F | Yes | Foods, meds | No | No | Yesc | Pos (1:10) | Pos | No data | Not tested | Not tested | Not tested | Janssen recommended | N/A |
| February 2, 2021 | 11 | 69 | F | Yes | Bee, foods | Yes | No | No | Pos (1:100) | Pos | No data | Pos (1:100) | Pos | No data | Janssen recommended | N/A |
| February 2, 2021 | 12 | 63 | F | Yes | Environmentals, food | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Did not receive | N/A |
| February 2, 2021 | 13 | 71 | F | Yes | Food | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Moderna (3/18, 4/15) | None |
| February 2, 2021 | 14 | 65 | F | Yes | Food | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Moderna (2/12) | None |
| February 2, 2021 | 15 | 76 | F | Yes | Food | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Moderna (4/30, 5/29) | None |
| February 26, 2021 | 16 | 61 | F | Yes | Unknown | No | Yes | No | Pos (1:10) | Neg | No data | Pos (1:10) | Pos | No data | Janssen recommended | N/A |
| February 26, 2021 | 17 | 68 | F | Yes | Unknown | No | No | No | Neg | Pos | Pos | Neg | Pos | Pos | Moderna (1/6, 3/1) | None |
| February 26, 2021 | 18 | 80 | F | Yes | Iodine and sulfa | No | No | No | Neg | Pos | Pos | Neg | Neg | Pos | Did not receive | N/A |
| February 26, 2021 | 19 | 74 | M | Yes | Venom, shellfish | No | No | No | Neg | No data | No data | Neg | No data | No data | Moderna (3/3, 3/31) | None |
| February 26, 2021 | 20 | 59 | F | Yes | Red dye, ampicillin | Yes | No | No | Neg | Pos | Pos | Pos (1:10) | Pos | Pos | Janssen recommended | N/A |
| February 26, 2021 | 21 | 59 | F | Yes | Venom, food, Moderna first dosage (immediate generalized pruritus, followed by asthma exacerbation, tongue swelling, myalgia) | No | No | No | Testing D/Cd | Testing D/Cd | Testing D/Cd | Pos (1:100) | Pos | Pos | Moderna (2/8, 4/12) | After desensitization, nonee |
| February 26, 2021 | 22 | 66 | F | Yes | Antibiotics | Yes | Yes | No | Neg | Pos | No data | Neg | Neg | No data | Pfizer (3/4, 3/25) | None |
| February 26, 2021 | 23 | 67 | F | Yes | Unknown | No | No | No | Neg | Pos | No data | Neg | Neg | No data | Did not receive | N/A |
| February 26, 2021 | 24 | 37 | F | Yes | Venom | No | No | No | Neg | No data | Neg | Neg | No data | Pos | Did not receive | N/A |
| March 19, 2021 | 25 | 59 | F | Yes | Venom | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Pfizer (4/6, 4/27) | None |
| March 19, 2021 | 26 | 65 | M | Yes | Flu vaccine | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Moderna (3/23, 4/20) | None |
| March 25, 2021 | 27 | 78 | M | Yes | Tdap | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Moderna (3/25, 4/22) | None |
| March 25, 2021 | 28 | 35 | F | Yes | Augmentin, doxycycline, hydrocodone | No | No | No | Not tested | Not tested | Not tested | Neg | Neg | No data | Moderna (3/25, 4/22) | None |
| March 25, 2021 | 29 | 71 | F | Yes | Egg | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Moderna (4/1, 4/29) | None |
| March 25, 2021 | 30 | 79 | F | Yes | Venom, lortab | No | No | No | Not tested | Not tested | Not tested | Neg | No data | No data | Moderna (4/1, 4/29) | None |
Abbreviations: AAAAI, American Academy of Allergy, Asthma, and Immunology; COVID-19, coronavirus disease 2019; D/C, discontinued; F, female; LPR, late phase reaction; M, male; meds, medications; mRNA, messenger RNA; N/A, not applicable; neg, negative; PCR, polymerase chain reaction; PEG, polyethylene glycol; pos, positive; prep, preparation; Pt, patient.
NOTE. Positive results were bolded in the table.
a
Skin testing performed using AAAAI-recommended protocol.
b
Confirmed through Tennessee Immunization Information System.
c
Confirmed by PCR.
d
Owing to systemic and local reactions to 1:100 dilution of Moderna in this patient, testing of the Pfizer vaccine was discontinued after the intradermal application of the 1:100 dilution of Pfizer, which revealed no reaction.
e
Patient given second dosage of Moderna after Moderna vaccine desensitization; subject of future publication.